Literature DB >> 24123289

Optimal auxiliary-covariate-based two-phase sampling design for semiparametric efficient estimation of a mean or mean difference, with application to clinical trials.

Peter B Gilbert1, Xuesong Yu, Andrea Rotnitzky.   

Abstract

To address the objective in a clinical trial to estimate the mean or mean difference of an expensive endpoint Y, one approach employs a two-phase sampling design, wherein inexpensive auxiliary variables W predictive of Y are measured in everyone, Y is measured in a random sample, and the semiparametric efficient estimator is applied. This approach is made efficient by specifying the phase two selection probabilities as optimal functions of the auxiliary variables and measurement costs. While this approach is familiar to survey samplers, it apparently has seldom been used in clinical trials, and several novel results practicable for clinical trials are developed. We perform simulations to identify settings where the optimal approach significantly improves efficiency compared to approaches in current practice. We provide proofs and R code. The optimality results are developed to design an HIV vaccine trial, with objective to compare the mean 'importance-weighted' breadth (Y) of the T-cell response between randomized vaccine groups. The trial collects an auxiliary response (W) highly predictive of Y and measures Y in the optimal subset. We show that the optimal design-estimation approach can confer anywhere between absent and large efficiency gain (up to 24 % in the examples) compared to the approach with the same efficient estimator but simple random sampling, where greater variability in the cost-standardized conditional variance of Y given W yields greater efficiency gains. Accurate estimation of E[Y | W] is important for realizing the efficiency gain, which is aided by an ample phase two sample and by using a robust fitting method.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  augmented inverse probability weighting; efficient estimation; efficient sampling; missing data; semiparametric model; two-phase sampling

Mesh:

Substances:

Year:  2013        PMID: 24123289      PMCID: PMC4021041          DOI: 10.1002/sim.6006

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  12 in total

1.  Exposure stratified case-cohort designs.

Authors:  O Borgan; B Langholz; S O Samuelsen; L Goldstein; J Pogoda
Journal:  Lifetime Data Anal       Date:  2000-03       Impact factor: 1.588

2.  On efficient two-stage adaptive designs for clinical trials with sample size adjustment.

Authors:  Qing Liu; Gang Li; Keaven M Anderson; Pilar Lim
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

3.  Optimal design and efficiency of two-phase case-control studies with error-prone and error-free exposure measures.

Authors:  R McNamee
Journal:  Biostatistics       Date:  2005-04-28       Impact factor: 5.899

4.  Using the whole cohort in the analysis of case-cohort data.

Authors:  Norman E Breslow; Thomas Lumley; Christie M Ballantyne; Lloyd E Chambless; Michal Kulich
Journal:  Am J Epidemiol       Date:  2009-04-08       Impact factor: 4.897

5.  HIV vaccine research: the way forward.

Authors:  Anthony S Fauci; Margaret I Johnston; Carl W Dieffenbach; Dennis R Burton; Scott M Hammer; James A Hoxie; Malcolm Martin; Julie Overbaugh; David I Watkins; Adel Mahmoud; Warner C Greene
Journal:  Science       Date:  2008-07-25       Impact factor: 47.728

6.  Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation.

Authors:  Fusheng Li; Uma Malhotra; Peter B Gilbert; Natalie R Hawkins; Ann C Duerr; Juliana M McElrath; Lawrence Corey; Steven G Self
Journal:  Vaccine       Date:  2006-06-27       Impact factor: 3.641

7.  Improved Horvitz-Thompson Estimation of Model Parameters from Two-phase Stratified Samples: Applications in Epidemiology.

Authors:  Norman E Breslow; Thomas Lumley; Christie M Ballantyne; Lloyd E Chambless; Michal Kulich
Journal:  Stat Biosci       Date:  2009-05-01

8.  Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity.

Authors:  Nina D Russell; Michael G Hudgens; Richard Ha; Colin Havenar-Daughton; M Juliana McElrath
Journal:  J Infect Dis       Date:  2003-01-06       Impact factor: 5.226

9.  Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach.

Authors:  Anastasios A Tsiatis; Marie Davidian; Min Zhang; Xiaomin Lu
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

10.  Efficient and robust method for comparing the immunogenicity of candidate vaccines in randomized clinical trials.

Authors:  Peter B Gilbert; Alicia Sato; Xiao Sun; Devan V Mehrotra
Journal:  Vaccine       Date:  2008-11-18       Impact factor: 3.641

View more
  6 in total

1.  Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials.

Authors:  Yunda Huang; Lily Zhang; Holly Janes; Nicole Frahm; Abby Isaacs; Jerome H Kim; David Montefiori; M Julie McElrath; Georgia D Tomaras; Peter B Gilbert
Journal:  Vaccine       Date:  2017-01-25       Impact factor: 3.641

2.  Toward computerized efficient estimation in infinite-dimensional models.

Authors:  Marco Carone; Alexander R Luedtke; Mark J van der Laan
Journal:  J Am Stat Assoc       Date:  2018-09-13       Impact factor: 5.033

3.  Errors in multiple variables in human immunodeficiency virus (HIV) cohort and electronic health record data: statistical challenges and opportunities.

Authors:  Bryan E Shepherd; Pamela A Shaw
Journal:  Stat Commun Infect Dis       Date:  2020-10-07

4.  Joint modeling of longitudinal and survival data with the Cox model and two-phase sampling.

Authors:  Rong Fu; Peter B Gilbert
Journal:  Lifetime Data Anal       Date:  2016-03-23       Impact factor: 1.588

5.  Efficient nonparametric inference on the effects of stochastic interventions under two-phase sampling, with applications to vaccine efficacy trials.

Authors:  Nima S Hejazi; Mark J van der Laan; Holly E Janes; Peter B Gilbert; David C Benkeser
Journal:  Biometrics       Date:  2020-09-28       Impact factor: 2.571

6.  HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens.

Authors:  Xiaoying Shen; Fatima Laher; Zoe Moodie; Arthur S McMillan; Rachel L Spreng; Peter B Gilbert; Ying Huang; Nicole L Yates; Nicole Grunenberg; M Juliana McElrath; Mary Allen; Michael Pensiero; Vijay L Mehra; Olivier Van Der Meeren; Susan W Barnett; Sanjay Phogat; Glenda E Gray; Linda-Gail Bekker; Lawrence Corey; Georgia D Tomaras
Journal:  Sci Rep       Date:  2020-02-07       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.